Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/17/2022 | $12.00 | Buy | Roth Capital |
Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), announced today that, on January 28, 2025, the Company will implement a 1-for-16 reverse split of its common stock following approval at its Special Meeting of Stockholders held on January 17, 2025. The reverse stock split will be effective as of the morning of January 28, 2025, and the Company's common stock will trade on a post-split basis at the beginning of trading on the same date under the existing trading symbol "REVB." The CUSIP number for the common stock following the reverse stock split will be 76135L606. The reverse stock split is intended to increase the market price per share of the Company's common s
– Dosing to Commence Mid-February – – Topline data expected Mid-Year – Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, announced today that it has started its PRIME (PReconditioning IMmunostimulatory Evaluation) Phase 1b clinical study of escalating doses of intravenously administered Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD). The US based multi-site placebo-controlled study will enroll up to forty patients in five cohorts of single escalating doses. "I am delighted to see the Revelation teams' hard work c
– A vote for Proposal 2 saves the Company over $200,000 per year – Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, wants to remind all shareholders to vote their proxies for the January 17, 2025 special meeting of stockholders. In particular, a vote for Proposal 2, the redomicile of the Company from Delaware to Nevada will save the Company at least $200,000.00 per year in franchise tax fees. All proposals in the proxy are important and the Board of Directors has suggested a vote for all proposals. Please vote by calling Advantage Pr
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, today reported its three and nine months ended September 30, 2024 financial results. Corporate Highlights Completed GMP manufacture of Gemini clinical drug supply Received net proceeds of $3.8 million from the exercise of warrants in August 2024 Announced Gemini induces dose dependent significant increases in IL-10 in healthy volunteers "The Revelation team continues to make significan
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, today reported its three and six months ended June 30, 2024 financial results. Corporate Highlights Completed dosing of its first in human phase 1 clinical study of Gemini Announced positive phase 1 clinical data of Gemini met the primary safety endpoint and showed statistically significant biomarker activity "The Revelation team has worked hard in the first half of 2024 to continue
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three months ended March 31, 2024 financial results. Results of Operations As of March 31, 2024, Revelation had $14.6 million in cash and cash equivalents, compared to $12.0 million as of December 31, 2023. The increase in cash and cash equivalents was primarily due to net cash received from financing activities, offset primarily by cash used for operating activities. Based on current operating plans and projections, Revelation believes that its curren
Roth Capital initiated coverage of Revelation Biosciences with a rating of Buy and set a new price target of $12.00
8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
SC 13G/A - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)
SC 13G - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)
SC 13G - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)
– A vote for Proposal 2 saves the Company over $200,000 per year – Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, wants to remind all shareholders to vote their proxies for the January 17, 2025 special meeting of stockholders. In particular, a vote for Proposal 2, the redomicile of the Company from Delaware to Nevada will save the Company at least $200,000.00 per year in franchise tax fees. All proposals in the proxy are important and the Board of Directors has suggested a vote for all proposals. Please vote by calling Advantage Pr
Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today announced the appointment of Lakhmir Chawla M.D. to the Company's Board of Directors (Board). "We are excited to welcome Dr. Chawla as an independent director to our Board," said James Rolke, Chief Executive Officer of Revelation. "Dr. Chawla brings decades of expertise and leadership in key areas such as nephrology, critical care medicine, drug development and strategic implementation. I am confident that he will provide valuable perspectives as we continue to execute our str
Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today announced that the Company has adjourned its 2023 Annual Meeting of Stockholders (the "Annual Meeting") originally scheduled to be held on June 9, 2023, to July 7, 2023, at 1:00 p.m., Eastern Time, or at such other time or such other date to which the meeting may be adjourned. On June 9, 2023, the Company called to order its Annual Meeting. At the Annual Meeting, there were not present in person or by proxy at least a majority of the Company's common stock outstanding as of th
4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)
4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)
4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)